CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]
Revenue	$ 0	$ 0	$ 0	$ 0
Costs and expenses:
Selling, general and administrative	151,000	221,000	522,000	878,000
Total	151,000	221,000	522,000	878,000
Operating loss	(151,000)	(221,000)	(522,000)	(878,000)
Total other expense
Interest expense	(1,000)	0
Interest income - sales-type sublease	0	0
Income (loss) from investments in unconsolidated entities, net	2,000	(156,000)	(266,000)	(1,287,000)
Total other expense	1,000	(156,000)	(266,000)	(1,287,000)
(Loss) income before income taxes	(150,000)	(377,000)	(788,000)	(2,165,000)
Provision for income taxes	0	1,000	0	2,000
Net (loss) income	(150,000)	(378,000)	(788,000)	(2,167,000)
Net loss attributable to noncontrolling interests	(23,000)	(57,000)	(118,000)	(325,000)
Net (loss) income attributable to U.S. Neurosurgical Holdings, Inc.	$ (127,000)	$ (321,000)	$ (670,000)	$ (1,842,000)
Basic net (loss) income per share attributable to U.S. NeuroSurgical Holdings, Inc (in dollars per share)	$ (0.02)	$ (0.04)	$ (0.08)	$ (0.24)
Diluted net (loss) income per share attributable to U.S. NeuroSurgical Holdings, Inc (in dollars per share)	$ (0.02)	$ (0.04)	$ (0.08)	$ (0.24)
Weighted average common shares outstanding, basic (in shares)	7,892,185	7,792,185	7,892,185	7,792,185
Weighted average common shares outstanding, diluted (in shares)	7,892,185	7,792,185	7,892,185	7,792,185